Medical and Scientific Conference Presentations

Results from the Phase 3 VALOR study and its open-label extension at ANA 2021 View Presentation
Oct 17, 2021
ICARE AD-US: Design of a Prospective, Single-arm, Multicenter, Noninterventional Real-world Study of Aducanumab in United States
Jul 29, 2021
Reduction in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline
Jul 26, 2021
Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients with Early Alzheimer’s Disease
Jul 26, 2021
Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE
Jul 26, 2021
Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease
Jul 26, 2021
Aducanumab EMBARK study design poster at AAN 2021
Apr 17, 2021
Aducanumab EMBARK study design audio presentation at AAN 2021
Apr 17, 2021
Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD
Mar 13, 2021
Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD
Mar 13, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
Mar 10, 2021
Aducanumab data review with Global Alzheimer's Platform Foundation
Feb 23, 2021
Aducanumab data review and Q&A with Alzheimer's Disease International
Jan 14, 2021
Aducanumab EMBARK study design at CTAD 2020
Nov 04, 2020
Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation)
Sep 23, 2020
Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation)
Sep 19, 2020
A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease
Aug 31, 2020
Aducanumab Phase 3 Topline Results at AAIC (encore virtual presentation)
Jul 29, 2020
Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation)
May 18, 2020
Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation)
Apr 02, 2020
Safety, PK, PD, and Exploratory Efficacy in Single and Multiple Dose Study of a SOD1 Antisense Oligonucleotide (BIIB067) Administered to Participants With ALS
May 07, 2019
CTAD Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease
Oct 26, 2018
CTAD Keynote: What Have We Learned from Aducanumab?
Oct 25, 2018
Cumulative Aducanumab Safety Data from PRIME: A Randomized, Double-blind, Placebo-controlled, Phase 1b Study
Oct 24, 2018
Aducanumab 48-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease
Oct 24, 2018
24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Jul 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Jul 22, 2018
Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Apr 22, 2018
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Apr 22, 2018
The Importance of Early Identification and Treatment of Alzheimer’s Disease
Mar 15, 2018
NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017
Apr 25, 2017
Source
AAN, April 25, 2017
NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017
Apr 25, 2017
Source
AAN, April 25, 2017
NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017
Apr 24, 2017
Source
AAN, April 24, 2017

Annual Stockholder Presentation

Hemophilia Spin-off Presentations